Wellbutrin
Hematopoietic and Lymphatic System Neoplasm
University of Rochester NCORP Research BasePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Hematopoietic and Lymphatic System Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TEONANACATL Roswell Park Cancer Institute | Phase 2 | BB |
Suvorexant Mayo Clinic | Phase 4 | B |
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine City of Hope Medical Center | Phase 2 | B |
Lactobacillus Plantarum Strain 299V Children's Oncology Group | Phase 3 | B |
Talzenna National Cancer Institute (NCI) | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Wellbutrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →